Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Catalysta Ventures

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 1
Portfolio companies 1
Rounds per year 0.09
Lead investments 0
Exits 1
Key employees Soon
Stages of investment
Early Stage Venture

Areas of investment

  • Pharmaceutical
  • Medical Device
  • Biotechnology
  • Medical
Summary

Catalysta Ventures appeared to be the VC, which was created in 2010. The main department of described VC is located in the Durham. The venture was found in North America in United States.

Among the various public portfolio startups of the fund, we may underline PhaseBio Pharmaceuticals For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Medical Device, Medical.

The typical case for the fund is to invest in rounds with 1 participant. In the next rounds fund is usually obtained by Johnson & Johnson Development Corporation, Hatteras Venture Partners, Fletcher Spaght, Inc..

The top amount of exits for fund were in 2018. The high activity for fund was in 2002. The fund is constantly included in less than 2 deals per year.

Read more

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
10X Capital -
2EP -
Dansk Erhvervsinvestering Copenhagen, Denmark, Hovedstaden
EIR Ventures Stockholm, Stockholm County, Sweden
Exome Asset Management New York, New York, United States
Intuit California, Mountain View, United States
Jincheng Boshi Beijing, Beijing, China
Kansas City Equity Partners Kansas City, Missouri, United States
Orbit Venture Partners -
Provident Capital Gurgaon, Haryana, India
Quantum Pacific Capital China, Hong Kong, Hong Kong Island
Ridgeline Ventures Boulder, Colorado, United States
Rukam Capital Trust Kyonggi-do, Seongnam, South Korea
Salesforce California, San Francisco, United States
Shenzhen Lanshi Venture Capital China, Guangdong, Shenzhen
Start'Act Gabès, Tunis, Tunisia
Telos Impact Belgium, Brussels, Brussels Hoofdstedelijk Gewest
Vidici Ventures -
Vinci Partners Brazil, Rio de Janeiro, Rio De Janeiro

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

PhaseBio Pharmaceuticals

Biotechnology
Medical
Medical Device
Pharmaceutical
25 Feb 2002 Pennsylvania, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Catalysta Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 1
Rounds per year 0.09
Peak activity year 2002
Lead investments 0
Exits 1

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

PhaseBio Pharmaceuticals

Biotechnology
Medical
Medical Device
Pharmaceutical
25 Feb 2002 Pennsylvania, United States
Crunchbase icon

Content report

The following text will be sent to our editors: